Projects and Grants per year
Personal profile
Education/Academic qualification
Post Doctoral Fellow, Stanford University
2019
Post Doctoral Fellow, New York Medical College
2018
Residency, New York Medical College
2015
Bachelor of Medicine, Bachelor of Surgery, Stanley Medical College
2011
-
25-NHL-43-JJ-PMC (90014496LYM1001): A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with B-cell Non-Hodgkin Lymphoma
Iragavarapu, C. (PI)
Janssen Research and Development LLC
5/22/25 → 5/22/27
Project: Research project
-
25-NHL-44-HR(GO45434): A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cel
Iragavarapu, C. (PI)
4/28/25 → 4/28/27
Project: Research project
-
24-NHL-40-AB (M22-128): A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Iragavarapu, C. (PI)
1/15/25 → 1/15/27
Project: Research project
-
24-NHL-39-FTI-PMC(FT522-101): A Phase 1 Study of FT522 in Combination with Rituximab in Participants with Relapsed/Refractory B-Cell Lymphoma
Iragavarapu, C. (PI)
Fate Therapeutics Incorporated
10/28/24 → 10/28/26
Project: Research project
-
24-NHL-38-AT-PMC (ALLO-501A-202): A Randomized, Open-Label Study Evaluating The Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-Cell Lymphoma (ALPHA 3)
Iragavarapu, C. (PI)
Allogene Therapeutics Incorporated
8/9/24 → 8/9/26
Project: Research project